In addition, EA may improve chronic neuropathic pain and depression‐like behaviors by modulating the CREB‐5‐hydroxytryptamine (5‐HT)/BDNF signaling pathway (Cong et al., 2021). Here, CREB1 is linked to depressive symptom measurement.